DiaMedica Therapeutics (DMAC) Current Assets (2017 - 2026)

DiaMedica Therapeutics has reported Current Assets for 10 years, with the latest figure at $52.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 39.93% year-over-year to $52.4 million; the trailing twelve-month figure through Mar 2026 stood at $52.4 million (up 39.93% YoY), and the FY2025 full-year result was $60.6 million, up 35.91% from the prior year.
• Current Assets for Q1 2026 stood at $52.4 million, down from $60.6 million in the prior quarter.
• The five-year high for Current Assets was $60.6 million in Q4 2025, with the low at $29.7 million in Q1 2023.
• Historically, Current Assets has averaged $44.7 million across 5 years, with a median of $44.6 million in 2024.
• Annual changes were most pronounced in 2022 — Current Assets soared 81.11% — and 2025, when it slumped 43.51%.
• DiaMedica Therapeutics' Current Assets stood at $33.8 million in 2022, then surged by 58.64% to $53.7 million in 2023, then decreased by 16.89% to $44.6 million in 2024, then surged by 35.91% to $60.6 million in 2025, then fell by 13.63% to $52.4 million in 2026.
• The last three Current Assets figures came in at $52.4 million (Q1 2026), $60.6 million (Q4 2025), and $56.2 million (Q3 2025), per Business Quant data.